Focus on behavioral interventions to prevent HIV transmission has been unsuccessful but the more recent intervention of using antiretroviral drugs has more promise, said Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health.
Focus on behavioral interventions to prevent HIV transmission has been unsuccessful but the more recent intervention of using antiretroviral drugs has more promise, said Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health.
Transcript
Why have previous HIV/AIDS prevention programs been ineffective?
For years, we focused on behavioral interventions. Which worked in some cases, but not all. We have sexually transmitted infections because behavioral interventions haven't been as successful as we might like them to be. The more recent intervention is the use of antiretroviral drugs for prophylaxis. So that is taking high-risk individuals and putting them on an antiretroviral drug to prevent HIV acquisition. If they're adherent, it does block it. But nonadherence is always, again, a behavioral issue. So that's something that has to be dealt with.
The second part is, even though we know PrEP, or pre-exposure prophylaxis works, a lot of countries haven't approved it. And it is a cost-effective measure, but the policies and the politics behind licensure and use and recommendation of these drugs in many countries of the world has lagged. And I think that is in part one of the reasons why we continue to see a rise in HIV infection in those countries.
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More
Posters Detail Effects—and Uncertainty—of Drug Pricing Negotiations
May 7th 2024Research into the Inflation Reduction Act evaluated payer concerns, patient and physician behavior, which patients will benefit from the first 10 drugs selected for price negotiation, and the ripple effect into Medicaid at the state level.
Read More